Alcoholic Hepatitis Market Size is anticipated to increase during the study period, 2019-2032 | Key Companies- DURECT Corporation, Novartis, and Others

DelveInsight's "Alcoholic Hepatitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Alcoholic Hepatitis, historical and forecasted epidemiology as well as the Alcoholic Hepatitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Latest Developmental Activities in the Alcoholic Hepatitis Treatment Landscape

• DURECT is currently conducting a Phase IIb study (AHFIRM), a randomized, double-blind, placebo-controlled trial targeting more than 60 clinical trial sites across the US, Europe, the UK, and Australian in subjects with severe alcohol-associated hepatitis. The primary outcome measured will be the 90-day survival rate for patients treated with larsucosterol compared to those treated with placebo plus standard of care. Secondary endpoints include 28-day survival, the rate of adverse events, Lille and MELD (prognostic scores), and time in the intensive care unit.

• Canakinumab is a human anti-IL-1β monoclonal antibody developed by Novartis. Its mode of action is based on the neutralization of 1β signaling, resulting in suppression of inflammation in patients with disorders of autoimmune origin. It is delivered intravenously to the patients. The drug is currently being evaluated in a multicenter, double blind, randomized (1:1), placebo controlled Phase II trial. The trial will follow patients up for 90 days and will be conducted in centers across the United Kingdom. Twenty-six patients will be recruited to each arm of the trial: total 52 patients. The primary endpoint of the trial is histological improvement of alcoholic hepatitis on liver biopsy after 28 days of treatment compared to baseline. Canakinumab is a licensed monoclonal antibody inhibitor of IL-1 and company believes that he drug may consequently reverse the adverse effects of the cytokine in patients with alcoholic hepatitis.

Explore more information on the latest breakthroughs in the Alcoholic Hepatitis Treatment Landscape @ Alcoholic Hepatitis Market Size- https://www.delveinsight.com/sample-request/alcoholic-hepatitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Alcoholic Hepatitis Overview
Alcoholic hepatitis (AH), as the name suggests, is hepatitis - inflammation of the liver - due to excessive intake of alcohol. Patients typically have a history of heavy alcohol intake, about 8-10 drinks per day. It is usually found in association with fatty liver, an early stage of alcoholic liver disease, and may contribute to fibrosis progression, leading to cirrhosis.

Key Takeaways from the Alcoholic Hepatitis Market Report

• According to DelveInsight's analysts, there are more cases for Alcoholic Hepatitis in males than females.

• As per Basra and Anand (2011), since up to 35% of alcoholics are estimated to have AH, the number of AH patients in the United States may be nearly 5 million and in Italy about 500,000.

• The leading Alcoholic Hepatitis Companies include Vital Therapies Inc, Mallinckrodt, DURECT Corporation, Novartis, and Others

• Promising Alcoholic Hepatitis Pipeline Therapies include Terlipressin, DUR 928, Canakinumab, and others

Alcoholic Hepatitis Epidemiology Segmentation in the 7MM
• Total Alcoholic Hepatitis Diagnosed Prevalent cases
• Alcoholic Hepatitis Gender-specific cases
• Alcoholic Hepatitis Severity-specific cases
• Alcoholic Hepatitis Treated cases

Download the report to understand which factors are driving Alcoholic Hepatitis epidemiology trends @ Alcoholic Hepatitis Epidemiological Insights- https://www.delveinsight.com/sample-request/alcoholic-hepatitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Alcoholic Hepatitis Market Insights
In most patients with alcoholic hepatitis, the illness is mild. The short-term prognosis is good, and no specific treatment is required. Hospitalization is not always necessary. Alcohol use must be stopped, and care should be taken to ensure good nutrition; providing supplemental vitamins and minerals, including folate and thiamine, is reasonable. Patients who are coagulopathic should receive vitamin K parenterally. Anticipate symptoms of alcohol withdrawal, and manage them appropriately. In contrast, patients with severe acute alcoholic hepatitis are at a high risk of early death, at a rate of 50% or greater within 30 days. Prednisolone and pentoxifylline are recommended for the treatment of severe alcoholic hepatitis, but uncertainty about their benefit persists.

Alcoholic Hepatitis Companies
• Vital Therapies Inc,
• Mallinckrodt,
• DURECT Corporation,
• Novartis, and Others

Alcoholic Hepatitis Pipeline Therapies
• Terlipressin
• DUR 928
• Canakinumab, and others

Find out more about the Alcoholic Hepatitis Pipeline Segmentation, Therapeutics Assessment, and Alcoholic Hepatitis Emerging Drugs @ Alcoholic Hepatitis Treatment Landscape- https://www.delveinsight.com/sample-request/alcoholic-hepatitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Alcoholic Hepatitis Market Report

• Coverage- 7MM

• Alcoholic Hepatitis Companies- Vital Therapies Inc, Mallinckrodt, DURECT Corporation, Novartis, and Others

• Alcoholic Hepatitis Pipeline Therapies- Terlipressin, DUR 928, Canakinumab, and others.

• Alcoholic Hepatitis Market Dynamics: Alcoholic Hepatitis Market Drivers and Barriers

• Alcoholic Hepatitis Market Access and Reimbursement, Unmet Needs

Dive deep into rich insights for drugs for Alcoholic Hepatitis Pipeline Companies and Therapies, click here @ Alcoholic Hepatitis Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/alcoholic-hepatitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Executive Summary of Alcoholic Hepatitis
3. Competitive Intelligence Analysis for Alcoholic Hepatitis
4. Alcoholic Hepatitis: Market Overview at a Glance
5. Alcoholic Hepatitis: Disease Background and Overview
6. Patient Journey
7. Alcoholic Hepatitis Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Alcoholic Hepatitis Unmet Needs
10. Key Endpoints of Alcoholic Hepatitis Treatment
11. Alcoholic Hepatitis Marketed Products
12. Alcoholic Hepatitis Emerging Therapies
13. Alcoholic Hepatitis: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Alcoholic Hepatitis
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Got Queries? Find out the related information on Alcoholic Hepatitis Mergers and acquisitions, Alcoholic Hepatitis Licensing Activities @ Alcoholic Hepatitis Recent Trends, and Future Perspectives- https://www.delveinsight.com/sample-request/alcoholic-hepatitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.